KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Receivables (2016 - 2026)

Pacific Biosciences Of California has reported Receivables over the past 16 years, most recently at $35.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 28.79% year-over-year to $35.4 million; the TTM value through Dec 2025 reached $35.4 million, up 28.79%, while the annual FY2025 figure was $35.4 million, 28.79% up from the prior year.
  • Receivables for Q4 2025 was $35.4 million at Pacific Biosciences Of California, up from $30.6 million in the prior quarter.
  • Over five years, Receivables peaked at $36.6 million in Q4 2023 and troughed at $12.9 million in Q1 2021.
  • A 5-year average of $27.6 million and a median of $29.4 million in 2024 define the central range for Receivables.
  • Biggest five-year swings in Receivables: skyrocketed 115.81% in 2022 and later fell 24.83% in 2024.
  • Year by year, Receivables stood at $24.2 million in 2021, then fell by 22.5% to $18.8 million in 2022, then skyrocketed by 94.91% to $36.6 million in 2023, then decreased by 24.83% to $27.5 million in 2024, then rose by 28.79% to $35.4 million in 2025.
  • Business Quant data shows Receivables for PACB at $35.4 million in Q4 2025, $30.6 million in Q3 2025, and $32.3 million in Q2 2025.